GeoPharma Announces Record Revenues in Third Quarter Results

Largo, FL -February 14, 2008 - GeoPharma, Inc. (NASDAQ:GORX)announced record revenues of $18.2 million for the third quarter representing more than a 200% increase in sales sequentially, as it reported financial results for the three and nine month periods ending December 31, 2007.

"We are pleased to report greatly improved financial results for the third quarter of our 2008 fiscal year; it demonstrates the benefit of the earlier executed Dynamic Health Products acquisition and showcases significant progress in our efforts to achieve critical mass of over a $100 million dollars in revenues for our 2009 Fiscal year which ends in March of 2009", stated GeoPharma CEO Mihir Taneja. "Although we are pleased with our financial progress, the third quarter was full of challenges that weighed on our results, which provides us with further confidence that we will see continued strength in the fourth quarter and the foreseeable future."

Q3 Financial Summary

Total revenues for the third quarter ended December 31, 2007 were $18.2 million as compared to the second quarter continuing operation revenues for the three months ended September 30, 2007 of $6.0 million, an increase of 203%

Total revenues for the nine months ended December 31, 2007 were $34 million an increase of 116% over the six months ended September 30, 2007.

Gross Profits for the third quarter ended December 31, 2007 were $3.6 million as compared to the second quarter continuing operations gross profits for September 2007 quarter of $1.2 million an increase of 200%.

Net loss for the December quarter 2007 was $(1.675) million as compared to the September 2007 net loss of $(1.9) million. Net loss per share for the December quarter 2007 was $(0.12) as compared to the September 2007 quarter net loss of $(0.16).

Selling, general and administrative expenses, exclusive of depreciation and amortization, were $5.3 million for the quarter ended December 2007 as compared to $3.7 million for the quarter ended September 2007. Increases this quarter were attributable to higher costs related to the addition of the DYHP acquisition in October 2007 in addition to additional legal and accounting costs and other business expansion such as rents, payrolls and related insurances.

Research and development ("R&D") expenditures for the three months ended December 31, 2007 totaled approximately $310,000 all of which was charged as an expense to operations as compared to $336,000 of R&D expense for September 2007.

CONFERENCE CALL INFORMATION

GeoPharma will host a conference call to discuss results on Thursday, February 14, 2008 at 11:30 (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Interested parties may participate in the conference call by dialing 1-888-680-0869 and entering pass code 78555682, 5 minutes prior to the initiation of the call. A replay of the conference call will be available from 1:30 PM (ET) on February 14 through February 21, by dialing 1-888-286-8010 and entering pass code 37538422.

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the "For Investors" section of the GeoPharma website at www.geopharmainc.com.

FORWARD LOOKING STATEMENTS

This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

Contact Information:

Alexander Nachman

Director of Investor and Media Relations

GeoPharma, Inc.

1-727-471-0850, ext. 243

ir@geopharmainc.com

GAAP FINANCIAL TABLES FOLLOW

GEOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended December 31,						Nine Months Ended December 31,
	2007			2006			2007			2006
Revenues:
PBM (a discontinued operation)	$	-		$	5,078,738		$	-		$	14,630,131
Distribution		11,217,987			3,374,219			14,435,258			9,869,392
Manufacturing		7,019,351			5,831,536			16,601,874			20,860,036
Pharmaceutical		-			-			41,188			251,845
Total revenues	$	18,237,338		$	14,284,493		$	31,078,320		$	45,611,404
Cost of goods sold:
PBM (a discontinued operation)		-			5,039,582			-			14,515,619
Distribution		9,042,503			1,224,369			10,779,944			3,986,597
Manufacturing (excluding depreciation and amortization presented below)		4,790,637			2,849,473			11,578,661			13,607,561
Pharmaceutical		828,743			654,640			2,402,125			813,571
Total cost of goods sold	$	14,661,883		$	9,768,064		$	24,760,730		$	32,923,348
Gross profit:
PBM (a discontinued operation)		-			39,156			-			114,512
Distribution		2,175,484			2,149,850			3,655,314			5,882,795
Manufacturing		2,228,714			2,982,063			5,023,213			7,252,475
Pharmaceutical		(828,743	)		(654,640	)		(2,360,937	)		(561,726	)
Total gross profit	$	3,575,455		$	4,516,429		$	6,317,590		$	12,688,056
Selling, general and administrative expenses:
Selling, general and administrative expenses		5,100,221			2,967,892			11,406,989			8,899,103
Stock option compensation expense		266,658			427,675			687,495			1,283,025
Depreciation and amortization		487,050			347,385			1,306,409			829,013
Selling, general and administrative expenses		5,853,929			3,742,952			13,400,893			11,011,141
Operating income (loss) before other income and expense, minority interest, income taxes and discontinued operations	$	(2,278,474	)	$	773,477		$	(7,083,303	)	$	1,676,915
Other income (expense), net:
Other income (expense), net		10,793			(410	)		11,318			163,889
Interest income (expense), net		(240,311	)		(33,790	)		(313,277	)		(62,406	)
Total other income (expense), net	$	(229,518	)	$	(34,200	)	$	(301,959	)	$	101,483
Income (loss) before minority interest, income taxes and discontinued operations	$	(2,507,992	)	$	739,277		$	(7,385,262	)	$	1,778,398
Minority interest benefit (expense)		202,495			319,998			644,951			984,328
Income tax benefit (expense)		729,951			(300,000	)		2,415,353			(888,000	)
Net income (loss) from continuing operations	$	(1,575,546	)	$	759,275		$	(4,324,958	)	$	1,874,726
Discontinued operations:
Revenues: PBM	$	-		$	-		$	2,925,139		$	-
Cost of goods sold: PBM		-			-			2,904,274			-
Gross profit: PBM	$	-		$	-			20,865		$	-
Selling, general and administrative expenses: PBM		-			-			20,785			-
PBM segment exit income (expense)		-			-			8,300			-
Discontinued operations net income (net of income tax)	$	-		$	-		$	8,380		$	-
Net income (loss)	$	(1,575,546	)	$	759,275		$	(4,316,578	)	$	1,874,726
Preferred stock dividends		100,001			75,000			308,336			225,000
Net income (loss) available to common shareholders	$	(1,675,547	)	$	684,275		$	(4,624,914	)	$	1,649,726
Basic income (loss) per share	$	(0.12)		$	0.07		$	(0.39	)		0.17
Basic weighted average number of common shares outstanding		13,805,912			9,818,924			11,967,112			9,877,749
Diluted income (loss) per share	$	(0.12	)	$	0.06		$	(0.39	)	$	0.14
Diluted weighted average number of common shares outstanding		13,805,912			13,191,605			11,967,112			13,290,210

See notes to condensed consolidated financial statements.